{"data":{"event":{"id":"83935e02-67fb-4faf-bbff-93732c44bcd4","slug":"stat-pharmalittle-we-re-reading-about-another-astrazeneca-trial-failure--aff4fed68e","title":"STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more","short_summary":"AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors","full_description":"AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors\n\nUpdate (2026-09-21): STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial. The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.\n\nUpdate (2026-09-23): STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more. As of next month, a loophole that allows Americans to personally import their medications by mail is closing\n\nUpdate (2026-10-27): STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more. A U.S. judge rejected a bid to block ‌Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss drugs","ledger_type":"harm","primary_domain_id":"fc7d617f-c9df-4b9f-b595-4408915ea380","event_status":"provisional","event_date":"2026-09-14T00:00:00.000Z","discovery_date":"2026-09-14T00:00:00.000Z","first_published_date":"2026-09-14T00:00:00.000Z","last_reviewed_date":"2026-10-27T00:00:00.000Z","geographic_scope":"International","affected_population":null,"base_impact_tier":1,"base_score":"1.00","attribution_multiplier":"0.1000","evidence_multiplier":"0.4000","realization_multiplier":"0.2000","durability_multiplier":"0.5000","current_event_score":"0.004000","confidence_level":"low","score_explanation":"Ingest update: independent source raised evidence; added a follow-up source. Score remains provisional until review. Follow-up ingest: independent source raised evidence; added a follow-up source. Follow-up ingest: independent source raised evidence; added a follow-up source.","methodology_version_id":"8745541b-0f8e-4d5a-9b47-5291d3813a8d","original_methodology_version_id":"8745541b-0f8e-4d5a-9b47-5291d3813a8d","published_at":"2026-09-14T14:00:48.541Z","created_at":"2026-09-14T14:00:48.541Z","updated_at":"2026-10-27T14:00:57.061Z","flags":[],"domain_name":"Other","domain_slug":"other","methodology_version":"0.2"},"contributions":[{"id":"95c2569f-c56b-4a5f-9055-6f0542d78943","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","model_id":"535014f7-c941-4d39-aa9b-8f9c1d3d07b7","role_description":"Unspecified system mentioned or implied by a news item. Remap to a named release when identified.","attribution_multiplier":"0.1000","credit_share":"1.0000","contribution_score":"0.004000","attribution_rationale":"News ingest does not infer a named model from the publisher alone. Attribution stays unspecified until a release is identified.","attribution_confidence":"medium","first_used_date":"2026-09-14T00:00:00.000Z","model_version_if_known":null,"review_status":"approved","created_at":"2026-09-14T14:00:48.557Z","model_slug":"unspecified-ai-system","model_name":"Unspecified AI system","identity_class":"unknown","is_internal":false,"family_name":"Unspecified","family_slug":"unknown-unspecified","organization_name":"Unknown","organization_slug":"unknown"}],"sources":[{"id":"3fdf2a0d-05d6-415c-85aa-8e02e67ea075","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","url":"https://www.statnews.com/pharmalot/2026/09/14/another-astrazeneca-trial-failure-novo-name-change/?utm_campaign=rss","canonical_url":"https://www.statnews.com/pharmalot/2026/09/14/another-astrazeneca-trial-failure-novo-name-change/?utm_campaign=rss","source_type":"journalism","publisher":"STAT","author":null,"publication_date":"2026-09-14T00:00:00.000Z","retrieved_at":"2026-09-14T14:00:48.565Z","title":"STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more","excerpt":"AstraZeneca disclosed that a breast cancer pill failed in a pivotal trial testing it as a first-line therapy in advanced tumors","content_hash":null,"source_reliability_class":"medium","is_primary_source":true,"is_independent":true,"is_peer_reviewed":false,"archived_url":null,"created_at":"2026-09-14T14:00:48.565Z"},{"id":"b9467121-d93a-4a58-8520-76ccef89a34e","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","url":"https://www.statnews.com/2026/09/21/alkermes-orexin-agonist-adhd-study/?utm_campaign=rss","canonical_url":"https://www.statnews.com/2026/09/21/alkermes-orexin-agonist-adhd-study/?utm_campaign=rss","source_type":"journalism","publisher":"STAT","author":null,"publication_date":"2026-09-21T00:00:00.000Z","retrieved_at":"2026-09-21T11:01:20.039Z","title":"STAT+: Alkermes’ orexin agonist shows potential to treat ADHD in early-stage trial","excerpt":"The drugmaker Alkermes said a therapy called an orexin agonist for the first time showed potential to treat people with ADHD in an early-stage study.","content_hash":null,"source_reliability_class":"medium","is_primary_source":false,"is_independent":false,"is_peer_reviewed":false,"archived_url":null,"created_at":"2026-09-21T11:01:20.039Z"},{"id":"ee99946e-4a38-4367-adf4-8b8d998d8044","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","url":"https://www.statnews.com/pharmalot/2026/09/23/loophole-closing-for-importing-meds-european-competitiveness/?utm_campaign=rss","canonical_url":"https://www.statnews.com/pharmalot/2026/09/23/loophole-closing-for-importing-meds-european-competitiveness/?utm_campaign=rss","source_type":"journalism","publisher":"STAT","author":null,"publication_date":"2026-09-23T00:00:00.000Z","retrieved_at":"2026-09-23T14:00:58.785Z","title":"STAT+: Pharmalittle: We’re reading about a closing loophole for importing meds, European competitiveness, and more","excerpt":"As of next month, a loophole that allows Americans to personally import their medications by mail is closing","content_hash":null,"source_reliability_class":"medium","is_primary_source":false,"is_independent":false,"is_peer_reviewed":false,"archived_url":null,"created_at":"2026-09-23T14:00:58.785Z"},{"id":"6e9c940c-a32f-417a-a490-05b0d3de865e","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","url":"https://www.statnews.com/pharmalot/2026/10/27/novo-setback-in-court-house-probe-into-big-pbms/?utm_campaign=rss","canonical_url":"https://www.statnews.com/pharmalot/2026/10/27/novo-setback-in-court-house-probe-into-big-pbms/?utm_campaign=rss","source_type":"journalism","publisher":"STAT","author":null,"publication_date":"2026-10-27T00:00:00.000Z","retrieved_at":"2026-10-27T14:00:57.017Z","title":"STAT+: Pharmalittle: We’re reading about a Novo setback in court, a House probe into big PBMs, and more","excerpt":"A U.S. judge rejected a bid to block ‌Eli Lilly from running what Novo Nordisk claims is a “deceptive” advertising campaign about weight loss drugs","content_hash":null,"source_reliability_class":"medium","is_primary_source":false,"is_independent":false,"is_peer_reviewed":false,"archived_url":null,"created_at":"2026-10-27T14:00:57.017Z"}],"claims":[{"id":"99798fcc-af52-4b43-a16f-d0b29a430107","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","claim_text":"STAT+: Pharmalittle: We’re reading about another AstraZeneca trial failure, a Novo name change, and more","claim_type":"outcome","claim_status":"supported","confidence_score":null,"created_at":"2026-09-14T14:00:48.573Z","updated_at":"2026-09-14T14:00:48.573Z"}],"revisions":[{"id":"3bf9291c-1d42-4759-ac67-04568010b395","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","model_id":null,"previous_score":"0.000000","new_score":"0.001000","previous_factors":{},"new_factors":{"evidence":0.1,"base_score":1,"durability":0.5,"attribution":0.1,"realization":0.2},"change_reason":"Auto-published from news ingest.","trigger_type":"news_ingest","trigger_source_ids":null,"reviewer_id":null,"review_status":"published","created_at":"2026-09-14T14:00:48.581Z"},{"id":"ad9edd85-8aa0-487f-8b0b-28865416b312","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","model_id":null,"previous_score":"0.001000","new_score":"0.002000","previous_factors":{"tier":1,"evidence":0.1,"base_score":1,"durability":0.5,"attribution":0.1,"realization":0.2},"new_factors":{"tier":1,"models":["535014f7-c941-4d39-aa9b-8f9c1d3d07b7"],"evidence":0.2,"base_score":1,"durability":0.5,"attribution":0.1,"realization":0.2},"change_reason":"Ingest update: independent source raised evidence; added a follow-up source.","trigger_type":"ingest_update","trigger_source_ids":["b9467121-d93a-4a58-8520-76ccef89a34e"],"reviewer_id":null,"review_status":"published","created_at":"2026-09-21T11:01:20.089Z"},{"id":"0e92ef80-1fd8-49af-b4ad-884420b14aca","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","model_id":null,"previous_score":"0.002000","new_score":"0.003000","previous_factors":{"tier":1,"evidence":0.2,"base_score":1,"durability":0.5,"attribution":0.1,"realization":0.2},"new_factors":{"tier":1,"models":["535014f7-c941-4d39-aa9b-8f9c1d3d07b7"],"evidence":0.3,"base_score":1,"durability":0.5,"attribution":0.1,"realization":0.2},"change_reason":"Ingest update: independent source raised evidence; added a follow-up source.","trigger_type":"ingest_update","trigger_source_ids":["ee99946e-4a38-4367-adf4-8b8d998d8044"],"reviewer_id":null,"review_status":"published","created_at":"2026-09-23T14:00:58.808Z"},{"id":"f1a6f66a-780a-47ca-9969-2e5fe04d6980","event_id":"83935e02-67fb-4faf-bbff-93732c44bcd4","model_id":null,"previous_score":"0.003000","new_score":"0.004000","previous_factors":{"tier":1,"evidence":0.3,"base_score":1,"durability":0.5,"attribution":0.1,"realization":0.2},"new_factors":{"tier":1,"models":["535014f7-c941-4d39-aa9b-8f9c1d3d07b7"],"evidence":0.4,"base_score":1,"durability":0.5,"attribution":0.1,"realization":0.2},"change_reason":"Ingest update: independent source raised evidence; added a follow-up source.","trigger_type":"ingest_update","trigger_source_ids":["6e9c940c-a32f-417a-a490-05b0d3de865e"],"reviewer_id":null,"review_status":"published","created_at":"2026-10-27T14:00:57.083Z"}],"secondary":[]},"methodology_version":"0.1"}